Compare McDonald's Corp (MCD) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs ResMed Inc. — how do they compare? McDonald's Corp trades at $235.48 (market cap $167.64B), while ResMed Inc. trades at $229.72 (market cap $31.89B). The key difference: McDonald's Corp is far larger — about 5.3× ResMed Inc.'s market cap, and McDonald's Corp pays the higher dividend (3.26%). Which is the better fit depends on your goals — on Pluang, investors hold McDonald's Corp for 164 Days and ResMed Inc. for 51 Days on average.
| MCD | RMD | |
|---|---|---|
Market Cap | $167.64B | $31.89B |
Volume | 11,320,306 | 618,314 |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $277.88 |
52-Week Low | $230.88 | $182.82 |
Typical Hold Time | 164 Days | 51 Days |
Enterprise Value | $221.41B | $31.24B |
Dividend Yield | 3.26% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $230.88, down 0.68% on the day, with a bearish technical signal from moving averages. The company shows steady revenue growth, reaching $26.89B in 2025, and has consistently beaten EPS estimates in recent quarters. Recent news highlights a new global growth strategy, 'McDonald's NEXT', focusing on automation and improved customer experience to counter competitive pressures and attract diners.
The outlook is mixed: strong fundamentals and a 58.7% analyst buy rating support upside to the $284.70 consensus target, but technical weakness and inflation-driven cost pressures pose near-term risks. The stock offers value through its dividend and defensive profile, yet investors must weigh execution risks of the new strategy against its long-term growth potential.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
